These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Sherbenou DW; Wong MJ; Humayun A; McGreevey LS; Harrell P; Yang R; Mauro M; Heinrich MC; Press RD; Druker BJ; Deininger MW Leukemia; 2007 Mar; 21(3):489-93. PubMed ID: 17252009 [TBL] [Abstract][Full Text] [Related]
9. E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib. Bennour A; Beaufils N; Sennana H; Meddeb B; Saad A; Gabert J J Clin Pathol; 2010 Aug; 63(8):737-40. PubMed ID: 20702476 [TBL] [Abstract][Full Text] [Related]
10. D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients. Leguay T; Desplat V; Marit G; Mahon FX Leukemia; 2005 Dec; 19(12):2332-3; author reply 2333-4. PubMed ID: 16281074 [No Abstract] [Full Text] [Related]
11. Roots of clinical resistance to STI-571 cancer therapy. Barthe C; Cony-Makhoul P; Melo JV; Mahon JR Science; 2001 Sep; 293(5538):2163. PubMed ID: 11567109 [No Abstract] [Full Text] [Related]
12. Roots of clinical resistance to STI-571 cancer therapy. Hochhaus A; Kreil S; Corbin A; La Rosée P; Lahaye T; Berger U; Cross NC; Linkesch W; Druker BJ; Hehlmann R; Gambacorti- Passerini C; Corneo G; D'Incalci M Science; 2001 Sep; 293(5538):2163. PubMed ID: 11569495 [No Abstract] [Full Text] [Related]
14. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy. Chien JH; Tang JL; Chen RL; Li CC; Lee CP Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297 [TBL] [Abstract][Full Text] [Related]
15. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680 [TBL] [Abstract][Full Text] [Related]
16. [Mechanism and overcome against drug resistance to imatinib for treatment of chronic myeloid leukemia]. Tauchi T; Oyashiki K Gan To Kagaku Ryoho; 2011 May; 38(5):749-53. PubMed ID: 21702118 [No Abstract] [Full Text] [Related]
17. BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay. Ono T; Miyawaki S; Kimura F; Kanamori H; Ohtake S; Kitamura K; Fujita H; Sugiura I; Usuki K; Emi N; Tamaki S; Aoyama Y; Kaya H; Naoe T; Tadokoro K; Yamaguchi T; Ohno R; Ohnishi K; Leuk Res; 2011 May; 35(5):598-603. PubMed ID: 21239056 [TBL] [Abstract][Full Text] [Related]
18. [STI571: the resistance organizes!]. Jeanteur P Bull Cancer; 2001 Sep; 88(9):819. PubMed ID: 11642306 [No Abstract] [Full Text] [Related]
19. BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? Legros L; Hayette S; Nicolini FE; Raynaud S; Chabane K; Magaud JP; Cassuto JP; Michallet M Leukemia; 2007 Oct; 21(10):2204-6. PubMed ID: 17541396 [No Abstract] [Full Text] [Related]
20. Cytogenetic and molecular mechanisms of resistance to imatinib. Hochhaus A Semin Hematol; 2003 Apr; 40(2 Suppl 2):69-79. PubMed ID: 12783379 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]